CA2464131A1 - Compositions et procede pour liberation controlee - Google Patents

Compositions et procede pour liberation controlee Download PDF

Info

Publication number
CA2464131A1
CA2464131A1 CA002464131A CA2464131A CA2464131A1 CA 2464131 A1 CA2464131 A1 CA 2464131A1 CA 002464131 A CA002464131 A CA 002464131A CA 2464131 A CA2464131 A CA 2464131A CA 2464131 A1 CA2464131 A1 CA 2464131A1
Authority
CA
Canada
Prior art keywords
factor
oligonucleotide
scaffold
composition
degrades
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002464131A
Other languages
English (en)
Inventor
Arthur H. Wong
Jacob M. Waugh
Michael D. Dake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revance Therapeuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2464131A1 publication Critical patent/CA2464131A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)

Abstract

L'invention a trait à des procédés et à des compositions permettant la libération contrôlée d'un agent actif. La composition contient un squelette oligonucléotidique et un facteur oligonucléotidique sensiblement complémentaire. Un agent actif est fixé au facteur oligonucléotidique. Les deux oligonucléotides sont dégradables de façon différentielle, de façon que la dégradation du squelette se fasse plus rapidement que celle du facteur. Lors de la dégradation du squelette, le facteur est libéré. L'agent actif peut être un agent thérapeutique ou un agent de diagnostic.
CA002464131A 2001-10-18 2002-10-17 Compositions et procede pour liberation controlee Abandoned CA2464131A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33634401P 2001-10-18 2001-10-18
US60/336,344 2001-10-18
PCT/US2002/033558 WO2003060142A2 (fr) 2001-10-18 2002-10-17 Compositions et procede pour liberation controlee

Publications (1)

Publication Number Publication Date
CA2464131A1 true CA2464131A1 (fr) 2003-07-24

Family

ID=23315656

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002464131A Abandoned CA2464131A1 (fr) 2001-10-18 2002-10-17 Compositions et procede pour liberation controlee

Country Status (5)

Country Link
EP (1) EP1446008A4 (fr)
JP (1) JP2005523890A (fr)
AU (1) AU2002365136A1 (fr)
CA (1) CA2464131A1 (fr)
WO (1) WO2003060142A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145813A1 (fr) 2008-03-04 2009-12-03 Qd Vision, Inc. Particules comprenant des nanoparticules, leurs utilisations, et procédés
WO2011031876A1 (fr) 2009-09-09 2011-03-17 Qd Vision, Inc. Formulations comprenant des nanoparticules
EP2475717A4 (fr) 2009-09-09 2015-01-07 Qd Vision Inc Particules comprenant des nanoparticules, leurs utilisations, et procédés
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
JP2016183434A (ja) * 2015-03-26 2016-10-20 国立大学法人京都大学 表面修飾基材

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985554A (en) * 1994-11-02 1999-11-16 Takeda Chemical Industries, Ltd. Method of probing the function of proteins or peptides encoded by partially sequenced cDNAs by inhibiting protein synthesis with antisense oligonucleotides
BR9809138A (pt) * 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica
WO1999050462A1 (fr) * 1998-03-27 1999-10-07 President And Fellows Of Harvard College Systemes d'inhibition bacteriens a base d'aptameres (abbis)
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
WO2000041732A1 (fr) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Compositions hydrogel pour l'administration controlee de vecteurs viraux, et leurs procedes d'utilisation
US6232068B1 (en) * 1999-01-22 2001-05-15 Rosetta Inpharmatics, Inc. Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies
AU1072801A (en) * 1999-10-01 2001-05-10 Essentia Biosystems, Inc. Gel-forming compositions
IN2014DN10834A (fr) * 2001-09-17 2015-09-04 Psivida Inc
US20030134811A1 (en) * 2001-10-09 2003-07-17 John Jackson Methods and compositions comprising hydroxyapatite useful for the administration of therapeutic agents

Also Published As

Publication number Publication date
AU2002365136A1 (en) 2003-07-30
WO2003060142A3 (fr) 2004-02-12
EP1446008A2 (fr) 2004-08-18
WO2003060142A2 (fr) 2003-07-24
WO2003060142A9 (fr) 2003-08-21
EP1446008A4 (fr) 2006-08-16
AU2002365136A8 (en) 2003-07-30
JP2005523890A (ja) 2005-08-11

Similar Documents

Publication Publication Date Title
Chandrasekaran Nuclease resistance of DNA nanostructures
Li et al. Advances in biological applications of self-assembled DNA tetrahedral nanostructures
US5561043A (en) Self-assembling multimeric nucleic acid constructs
JP2022050550A (ja) 核酸キャリア及び治療上の使用方法
Farokhzad et al. Nanoparticle–aptamer bioconjugates for cancer targeting
JP2005533794A (ja) アプタマー−毒素分子およびこれを使用する方法
EP2976109B1 (fr) Administration cellulaire d'agents intercalants de l'adn
JP2019513692A (ja) 核酸キャリア及び治療上の使用方法
EP1407787A1 (fr) Procede facilitant le transfert d'acides nucleiques
CA2464131A1 (fr) Compositions et procede pour liberation controlee
AU2002230922B2 (en) Non-invasive method for detecting target RNA
WO2023171598A1 (fr) Procédé de détection d'oligonucléotides à l'aide d'une sonde
US9579396B2 (en) Finite fully addressable nucleic acid nanostructures as nanocarriers for delivery of pharmaceuticals
KR20110055693A (ko) 트랜스펙션제
AU2002230922A1 (en) Non-invasive method for detecting target RNA
WO2007047986A1 (fr) Procede et systeme de distribution d'un acide nucleique dans une cellule cible
WO2009057812A1 (fr) Nanoparticule hybride organique-inorganique composée d'un conjugué d'acide nucléique ayant du polyéthylèneglycol lié à celui-ci et de phosphate de calcium
WO1995002422A1 (fr) Methode pour conjuguer des nucleotides et des nucleosides avec des composes contenant du disulfide, du maleimide et du thiol
WO2024058008A1 (fr) Procédé de détection d'oligonucléotides utilisant une sonde
Doherty et al. Aptamers in neuro-oncology: An emerging therapeutic modality
Matsuura et al. On− Off Switching of Gene Expression Regulated with Carbohydrate− Lectin Interaction
US20050153321A1 (en) Libraries of multiple-ligand-conjugated nucleic acids
US20230304992A1 (en) Growth and site-specific organization of micro-scale bimolecular devices on living cells
WO2023204045A1 (fr) Procédé de mesure d'un analyte avec une sensibilité ultra-élevée
CN112424371B (en) Detection assay for protein-polynucleotide conjugates

Legal Events

Date Code Title Description
FZDE Discontinued